ASPIRA - New Disposable Breath-Actuated Inhaler Unveiled
Cost-effective, improved drug delivery design that records 200 individual doses
Copenhagen September 13, 2006. Bang & Olufsen Medicom, an innovative drug delivery device solutions provider for the pharmaceutical industry, has today unveiled its new disposal breath-actuated inhaler – AspiraTM. The product will be on public display for the first time at the EASD – European Association for the Study of Diabetes - conference which begins this week in Copenhagen, Denmark. AspiraTM is designed for use with liquid drug formulations suitable for pMDIs (pressurized metered dose inhalers). The inhaler offers a cost-effective and improved pulmonary drug delivery for treating diseases, including diabetes.
Diabetes is now recognised as a global epidemic, with growth projections estimated to be in the region of 171 million sufferers in 2000 up to 366 million by the year 2030[i]. It is estimated that currently 48 million people in Europe have the disease with associated healthcare costs of approximately €256 billion. Of the two types of diabetes, type 2 is said to be at the origin of this epidemic, generally occurring in people over 40 years of age who are overweight, however children are increasingly affected. In type 2 diabetes, the body does not effectively use nor produce enough insulin to manage blood sugar levels, and eventually most people with type 2 diabetes will need insulin to achieve blood sugar control.
Recently, the first insulin inhaler was launched on the market creating a new opportunity for diabetics who have needle-phobia or those who do not like taking the injectable form of insulin. Advances in inhalers have also made the daily management of diseases easier for patients. For example - breath-actuated inhalers - which are automatically activated when the user inhales from the mouthpiece. This automatic release of the medication removes a large stumbling block for patients who have trouble co-ordinating their movements with conventional press-and-breath inhalers and is therefore especially suitable for children and the elderly. In addition Aspira TM holds a unique patent which reduces the particle flow rate thus ensuring improved drug delivery to the lungs.
Another key feature for the AspiraTM breath-actuated inhaler is an integrated dose-counter, which can record up to 200 individual doses. This feature is important for people who have difficulties tracking their medication and can help with patient compliance issues. The dose counter will only register fired doses and will therefore reliably inform the patient of doses taken and remaining in the canister.
Speaking at the unveiling, the Head of Sales and Marketing, Christian Husegaard said; “AspiraTM is a unique solution for the treatment of Diabetes, as it is optimized for improved drug delivery using a patented technology to reduce the flow rate. In addition, it is a cost-effective alternative, due to a reservoir technology which reduces the daily cost of administering the treatment. The device is also aimed at helping patient compliance as it shares a unique dose-counter technology platform currently used in our inhaler range developed for Asthma and Chronic Obstructive Pulmonary Disease (COPD).”
About Bang & Olufsen Medicom
Bang & Olufsen Medicom, a wholly owned subsidiary of the Bang & Olufsen group, is a leading expert in the design, development and supply of innovative drug delivery device solutions and sensor based technologies. The current product range includes; inhalers, tablet reminders and injection pens with a focus on patient compliance. Bang & Olufsen Medicom offers concept development, engineering and manufacturing services to clients with options to license its intellectual property. For more information you can visit: http://www.medicom.bang-olufsen.com
Image bank:
To download images of the Inhaler please visit the Bang & Olufsen Medicom center: http://mediacenter.bang-olufsen.dk/MediaCenter/mc.nsf
Simply register the first time you visit. Search: AspiraTM or Medicom.
For more information you can contact: Treasa Devine, PR Manager, B&O Medicom + 4561555961
[i] Diabetes Care,”Global Prevalence of Diabetes, estimates for the year 2000 and projections for 2030”. Volume 27;1047-1053, 2004.